Aspen Pharmacare Holdings Ltd
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
660 / 1328
Position in country
253 / 336
Return on Assets, %
3.6
-2.7
Net income margin, %
10.9
2.8
EBITDA margin, %
24.5
10.8
Debt to Equity, %
42.1
19.2
Intangible assets and goodwill, %
52.8
3.6
Revenue CAGR 3Y, %
6.5
8.5
Revenue Y, % chg
-0.3
0.5
P/E
20
22.7
P/BV
1.1
1.5
P/S
2.2
2.3
EV/S
2.8
2.4
EV/EBITDA
14.9
7.4
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
6.5
51.3
Forward P/E
12.1
15.6
Dividend Yield, %
1.5
1.7
Forward Dividend Yield, %
2
0.2
Expected dividend per share
0.2
0
Dividend Ex Date
2023-09-21
Competitors
Ranks
-
Novo Nordisk A/S
00%
-
Sanofi SA
00%
-
AstraZeneca PLC
00%
-
Eli Lilly and Co
00%
-
Roche Holding AG
00%
-
Aspen Pharmacare Holdings Ltd
00%
-
Novartis AG
00%
-
Johnson & Johnson
00%
-
Merck & Co Inc
00%
-
Pfizer Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
South Africa
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
5239.9
Ticker
APNHY.PK
ISIN
US04530Y1064
IPO date
1994-12-05
Availability on Russian exchanges
No
Reporting for
2024-03-04
Date fact. publication of reports
2023-12-31
Company Description
Aspen Pharmacare Holdings Limited is a South Africa-based global specialty and branded pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both active pharmaceutical ingredients (APIs) and finished dose form. The Company is focused on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments: Manufacturing and Commercial Pharmaceuticals. The Manufacturing segment relates to the manufacture and sale of APIs and finished dose form products to third-party customers. Its Commercial Pharmaceuticals segment comprises Regional Brands and Sterile Focus Brands that include Anaesthetics and Thrombosis products. It operates approximately 23 manufacturing facilities on six continents. Its manufacturing capabilities cover a wide variety of product-types, including orals, liquids, steriles, biologicals and APIs.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: